ArticleLeukemia2025
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632).
Frances M Cole et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papertrialcites it